Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL · Alpha
██.█% Sign up free to reveal

Eli Lilly & Co (LLY) AI Forecast

Our AI analyzed Eli Lilly & Co. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$LLY Neutral Signal Full forecast available
Sign Up Free

Eli Lilly & Co (LLY) Stock Forecast Sept. 24, 2026

Eli Lilly & Co (LLY) AI Stock Price Forecast & Investment Analysis

Eli Lilly & Co Stock Price Chart and Technical Analysis

Loading chart...

Eli Lilly & Co (LLY) - Comprehensive Stock Analysis & Investment Research

Deep dive into Eli Lilly & Co's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Eli Lilly & Co Investment Summary

When evaluating whether Eli Lilly & Co (LLY) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Eli Lilly & Co (LLY) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $1083 billion, the company is classified as a mega-cap stock, typically characterized by high stability and strong institutional backing.

Financial Performance Analysis

Our comprehensive financial analysis covers Eli Lilly & Co's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Eli Lilly & Co along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Eli Lilly & Co is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Eli Lilly & Co

Sign Up Free
Corporate Identity

Eli Lilly & Co (Stock Symbol: LLY) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the NYSE exchange.

Leadership & Workforce

Detailed information about Eli Lilly & Co's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Eli Lilly & Co...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Eli Lilly & Co...

Unlock Full Company Profile

Get complete details about Eli Lilly & Co

Sign Up Free
Revenue & Growth Analysis

Eli Lilly & Co generates annual revenues of $80 billion , demonstrating substantial market presence and operational scale.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Eli Lilly & Co...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Eli Lilly & Co...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Eli Lilly & Co...

Unlock Financial Analysis

Get complete financial metrics for Eli Lilly & Co

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Eli Lilly & Co's AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Eli Lilly & Co strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mega-cap market leader, the company commands significant market influence, enjoying substantial competitive moats including brand recognition, scale economies, and extensive distribution networks. Mega-cap status typically brings advantages in capital access, talent acquisition, and partnership opportunities, while also attracting the highest levels of institutional investor and analyst coverage.

Industry Competitive Landscape

Eli Lilly & Co competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Margin & Pricing Power Analysis

The company maintains a 83.4% gross margin which reflects strong pricing power and/or low direct production costs relative to revenue. Gross margins are only comparable within an industry, so read this level against the company's peers rather than the market as a whole.

Asset Utilization Efficiency

Asset turnover ratio of 1.81x indicates a high revenue base relative to the assets employed. Asset turnover is set largely by the business model, so the ratio is informative against the company's own industry rather than in isolation.

Financial Strength & Leverage

Current ratio of 1.35 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Eli Lilly & Co (LLY) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Eli Lilly & Co stock analysis. Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.

Deep dive into Eli Lilly & Co's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Eli Lilly & Co stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Eli Lilly & Co: With a P/E ratio of 40.56, the market highly values future growth prospects.

P/E Ratio 40.56x
P/B Ratio 110.24x
Market Cap $1.08T
Dividend Yield 0.53%
EPS $29.80
Book Value/Share $10.44
Revenue/Share $84.63
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Eli Lilly & Co converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Eli Lilly & Co:

Gross Margin 83.4%
EBT Margin 130.5%
Tax Rate 20.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Eli Lilly & Co's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Eli Lilly & Co: A current ratio of 1.35 shows adequate liquidity.

Current Ratio 1.35x
Quick Ratio 1.00x
D/E Ratio 3.36x
Financial Leverage 4.47x
Working Capital $16.93B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Eli Lilly & Co's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Eli Lilly & Co:

Operating Cash Flow $28.08B
OCF Growth YoY 156.8%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Eli Lilly & Co uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Eli Lilly & Co: An asset turnover of 1.81x demonstrates efficient asset utilization.

Asset Turnover 1.81x
Receivables Turnover 4.0x
Inventory Turnover 0.8x
Fixed Assets Turnover 2.7x
Days Sales Outstanding 92 days
Days Inventory 463 days
Payables Period 169 days
Cash Conversion Cycle 387 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Eli Lilly & Co's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Eli Lilly & Co: With annual revenue of $79665M, Eli Lilly & Co operates at significant scale.

Income Statement
Total Revenue $79.67B
R&D Expense $14.60B
SG&A Expense $12.24B
Cost of Goods Sold $13.22B
Balance Sheet Highlights (USD millions)
Total Current Assets $64.67B
Cash & Short-term Investments $8.95B (20.4% of assets)
Accounts Receivable $20.08B (45.7% of assets)
Inventory $16.79B (38.2% of assets)
Total Liabilities $33.00B (75.2% of assets)
Short-term Debt $41.63B (94.8% of assets)
Dividend & Shareholder Information
Dividends Per Share $6.15
Payout Ratio 20.6%
Shares Outstanding 941M

Latest Eli Lilly & Co Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Eli Lilly & Co (LLY) stock price and investment outlook.

📰 Loading...

Where LLY sits on the market map

Explore the map →

Eli Lilly & Co Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Eli Lilly & Co (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Eli Lilly & Co Stock Forecast

How accurate are Eli Lilly & Co stock predictions?

A per-ticker accuracy statistic for LLY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Eli Lilly & Co stock price forecasts?

Our analysis considers Eli Lilly & Co's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Eli Lilly & Co a good investment in 2026?

Based on our AI analysis, Eli Lilly & Co shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Eli Lilly & Co forecasts updated?

Eli Lilly & Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Eli Lilly & Co?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...